Effects of different protocols of defocused high-power laser on the viability and migration of myoblasts-a comparative in vitro study

Autor(es)

Brochado, Fernanda Thome ; Marmora, Belkiss Camara ; Campos, Paloma Santos ; Schmidt, Tuany Rafaeli ; Santos Fernandes, Kristianne Porta ; Bussadori, Sandra Kalil ; Santos, Lucas Goncalves ; Wagner, Vivian Petersen ; Lamers, Marcelo Lazzaron ; Martins, Manoela Domingues

• Tipo de documento: Artigo Científico
• Fonte: Lasers in Medical Science; v. 37, n. 9, p. 11-pg., 2022-09-20.

Resumo

The aim of the present study was to analyze for the first time the effect of photobiomodulation therapy (PBMT) using defocused high-power laser (DHPL) in myoblast cell line C2C12 viability and migration and compare them with low-power laser therapy. Cells were divided into 9 groups: Sham irradiation 10% fetal bovine serum (FBS); Sham irradiation 5%FBS; low-power laser 0.1 W; DHPL 810 1 W; DHPL 810 2 W; DHPL 980 1 W; DHPL 980 2 W; DHPL dual 1 W; DHPL dual 2 W. To simulate stress conditions, all groups exposed to irradiation were maintained in DMEM 5% FBS. The impact of therapies on cell viability was assessed through sulforhodamine B assay and on cells migration through scratch assays and time-lapse. Myoblast viability was not modified by PBMT protocols. All PBMT protocols were able to accelerate the scratch closure after 6 and 18 h of the first irradiation (p < 0.001). Also, an increase in migration speed, with a more pronounced effect of DHPL laser using dual-wavelength protocol with 2 W was observed (p < 0.001). In conclusion, the diverse PBMT protocols used in this study accelerated the C2C12 myoblasts migration, with 2-W dual-wavelength outstanding as the most effective protocol tested. Benefits from treating muscle injuries with PBMT appear to be related to its capacity to induce cell migration without notable impact on cell viability. (AU)

• Processo FAPESP: 16/21785-4 - Relação da via de sinalização BDNF/TRKB com a agressividade e perfil de células tronco tumorais de neoplasias malignas de glândula salivar
• Beneficiário: Vivian Petersen Wagner
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado